Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu
Secondary Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL
  • WELCOME

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: filibuvir

Discontinued But Not Forgotten: HCV Drugs That Did Not Make It

Posted on February 23, 2015 by Harald — No Comments ↓

I find it useful to look back and review drug candidates that were stopped in development.  In case of insufficient efficacy, i.e., not enough of a VL reduction or early viral rebound, everyone can sympathize with the decision to discontinue Continue reading Discontinued But Not Forgotten: HCV Drugs That Did Not Make It→

Share this:

  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to print (Opens in new window) Print
  • Click to email a link to a friend (Opens in new window) Email

Like this:

Like Loading...
Posted in Recent Literature | Tagged adverse events, antibiotic blog, attrition rate, BMS-986094, cardiac toxicity, development stop, filibuvir, HCV, hepatotoxicity, IDX-184, lack of transparency in reporting, NS5B, nucleoside NS5B inhibitor, polymerase inhibitors, PSI-938, renal toxicity, reporting bias, VX-222 | Leave a reply

Primary Sidebar Widget Area

Posts and Blogs

  • Microbiological Response as Primary Efficacy Endpoint for Antibacterials
  • REGULATORY INTERACTIONS  – 1
  • PK/PD of BIOLOGICALS
  • NANOBODIES FOR AUTOIMMUNE DISEASES
  • About A Prepared Mind – In R&D
  • The 10 x ’20 Initiative – A Retrospective
  • BAFF / APRIL Inhibitors Homing in on IgAN
  • THE UTILITY OF FUTILITY
  • Sulopenem uUTI – Does It Suffice?
  • PUBLICATION OVERACHIEVERS

Subscribe to AllphasePharma Blogs via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Tags

ABSSSI Achaogen Allphase Pharma Consulting aminoglycoside antibiotic blog Avelox Bayer Ceftazidime/avibactam cIAI ciprofloxacin colistin Cubicin Cubist cUTI dalbavancin Dalvance daptomycin delafloxacin eravacycline FDA fosfomycin GSK Harald Reinhart levofloxacin Merck meropenem moxifloxacin MRSA Novartis omadacycline Orbactiv oritavancin P. aeruginosa Pfizer PK/PD plazomicin QIDP solithromycin tedizolid tetracycline Tetraphase tigecycline Tygacil vancomycin VAP

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • WELCOME
  • Email
Copyright © 2025 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
%d